作者：
Meletios A,Dimopoulos [1]
;
Francesca,Gay [2]
;
Fredrik,Schjesvold [3]
;
Meral,Beksac [4]
;
Roman,Hajek [5]
;
Katja Christina,Weisel [6]
;
Hartmut,Goldschmidt [7]
;
Vladimir,Maisnar [8]
;
Philippe,Moreau [9]
;
Chang Ki,Min [10]
;
Agnieszka,Pluta [11]
;
Wee-Joo,Chng [12]
;
Martin,Kaiser [13]
;
Sonja,Zweegman [14]
;
Maria-Victoria,Mateos [15]
;
Andrew,Spencer [16]
;
Shinsuke,Iida [17]
;
Gareth,Morgan [18]
;
Kaveri,Suryanarayan [19]
;
Zhaoyang,Teng [19]
;
Tomas,Skacel [19]
;
Antonio,Palumbo [20]
;
Ajeeta B,Dash [19]
;
Neeraj,Gupta [19]
;
Richard,Labotka [19]
;
S Vincent,Rajkumar [21]
;
TOURMALINE-MM3 study group
作者单位：
Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. Electronic address: mdimop@med.uoa.gr.
[1]
Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria City of Health and Science of Turin, Turin, Italy.
[2]
Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway.
[3]
Department of Hematology, Ankara University, Ankara, Turkey.
[4]
Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
[5]
Department of Internal Medicine II, University of Tuebingen, Tuebingen, Germany.
[6]
Department of Internal Medicine V, University Medical Hospital and National Center of Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
[7]
Fourth Department of Medicine-Hematology, FN and LF UK Hradec Králové, Hradec Králové, Czech Republic.
[8]
Department of Hematology, University Hospital Hôtel Dieu, University of Nantes, Nantes, France.
[9]
Department of Internal Medicine, Seoul St Mary's Hospital, Seoul, South Korea.
[10]
Department of Haematology, Medical University of Lodz, Multidisciplinary Provincial Centre of Traumatology and Oncology Nicolas Copernicus in Lodz, Lodz, Poland.
[11]
Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore and Cancer Science Institute of Singapore, National University of Singapore, Singapore.
[12]
Department of Haematology, The Royal Marsden Hospital, London, UK; Division of Molecular Pathology, The Institute of Cancer Research ICR, London, UK.
[13]
Department of Hematology, Amsterdam University Medical Center, VU University Amsterdam, Cancer Center Amsterdam, Netherlands.
[14]
Department of Hematology, University Hospital of Salamanca, CIC, IBMCC, Salamanca, Spain.
[15]
Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VA, Australia.
[16]
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
[17]
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
[18]
Millennium Pharmaceuticals, Cambridge, MA, USA.
[19]
Millennium Pharmaceuticals, Cambridge, MA, USA; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria S Giovanni Battista, Torino, Italy; Center for Hematology and Oncology, University Hospital Zürich, Zürich, Switzerland.
[20]
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
[21]
DOI
10.1016/S0140-6736(18)33003-4
PMID
30545780
发布时间
2019-02-15
换一批
换一批
